Given anti-amyloid "Alzheimer's drug" controversies, why do we still overlook the benefits of targeted cognitive interventions? (opens in new tab)

This recent and com­pre­hen­sive Cochrane review of the anti-amy­loid drug evi­dence is attract­ing much attention. Anti-amy­loid Alzheimer’s drugs show no clin­i­cal­ly mean­ing­ful effect (Cochrane): “Drugs that tar­get amy­loid beta pro­teins in the brain like­ly have no clin­i­cal­ly mean­ing­ful pos­i­tive effects, while increas­ing the risk of bleed­ing and swelling in the brain, a new Cochrane review has…